Degradation Assays & Target Engagement Patents: Leaders 2026
Degradation Assays and Target Engagement Patents
54.2% concentration. The top 5 of 70 ranked assignees together hold 143 of 264 records in scope — a tight core around a long tail of single-digit filers. Filings rose from 7 records in 2017 to a peak of 40 in 2019, then eased; the last fully comparable window shows 2021's 16 records dropping to 13 in 2024, a 19% decline. Treat 2025 and 2026 figures as incomplete rather than as evidence of continued decline.
- 1DANA FARBER CANCER INSTITUTE INC60
- 2JANSSEN BIOTECH INC38
- 3H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC21
- 4THE BROAD INST INC13
- 5MEDIMMUNE LTD11
See the full degradation assays and target engagement analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this patent landscape
Who are the leading patent holders in degradation assay and target engagement technology?
The ranking covers 70 assignees, with the leading filer holding 60 of the 264 records in scope — far ahead of fifth place at 11 and tenth place at 8. The top 5 assignees together hold 54.2% of all records, so leadership is concentrated among a small group of academic cancer institutes and pharma companies rather than spread evenly. Below the top 10, filers typically hold only a handful of records each, forming a long tail rather than a second tier of comparable size.
Is patent filing activity in this space growing or slowing down?
Filing peaked at 40 records in 2019 and has since cooled; the last fully comparable three-year window shows 2021’s 16 records falling to 13 by 2024, a 19% decline. Figures for 2025 and 2026 look lower still, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. A fair read is that the field passed its filing peak in 2019 and has settled at a lower but still active rate through 2024.
What technology areas do these patents actually cover?
Medicinal preparations (IPC class A61K) appear on 54.5% of the 264 records, making it the dominant class, followed by heterocyclic compounds (C07D) at 33.3% and material analysis and testing methods (G01N) at 31.1%. Genetic engineering, therapeutic activity, peptides and proteins, and enzyme/DNA measurement classes each sit near 18.6%, with steroid-related claims the smallest tracked segment at 6.1%. Because most records carry several IPC codes at once, these percentages overlap rather than summing to a whole field.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Degradation Assays and Target Engagement covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.